الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Microbiological assessment of clinical stool samples 6.1 Isolated pathogenic bacteria: H. pylori was Serological detected in ten out of 25 clinical stools by RapiCardTMInsta Test The positive clinical stool were distinct pink colored band appeared on test regions, in addition to a pink line on the control line region. H. pylori was incidence in clinical stool and showed typical colonies, translucent to pale grayish on blood agar with small 0.5 to 1 mm in size. In very young cultures H. pylori may appear as almost straight rods on microscopy. 6.2 Identification of bacterial isolates The bacterial isolate from clinical stool were identified according to their morphological, cultural characteristics and consumption of broth manual some biochemical tests according to (Bergey’s manual, 2009) and confirmed by VITIK2 system. The identified bacterial isolate were belonging to main bacterial family (Helicobacteraceae). H. pylori was isolated and enumerated onto plates of blood media. Shaped of the grown colonies were translucent to pale grayish, smooth texture, with no pigmentation. The cells were facilitative anaerobic, gram negative, straight rods to long spiral, and motile. Beta Hemolysis on blood agar was recorded. The isolates were positive catalase, coagulase, Oxidase and Urease. The Biochemical characteristics of H. pylori were confirmed with excellent probability 98% after full Biochemical identification by VITIK2 system as well as the susceptibility information was provided. 6.3 Antibacterial activity of Bifidocin B and Yeast extract: Two prebiotics, bifidocin B and yeast extract a good alternative to the use of traditional antibacterial treatment. Two prebiotics were assessed by inhibition zones diameter against H. pylori, S. aureus, E. coli, showed the different susceptibilities towards bifidocin B and yeast extract at concentration 6.125,12.5 and 25 mg and standard error of clear zones of inhibition. E. coli was exhibited 12.6, 14.25, 18.5 of bifidocin B and 13.34, 14.75 and 18.16 mm of yeast extract respectively. H. pylori was exhibited 12.9, 15.83, 22.16 of bifidocin B, and 13.23, 15.33, 18.61 mm of yeast extract respectively. S. aureus was recorded 11.16, 15.33, 18.83 of bifidocin B and 10.15,12 and 16.4 mm of yeast extract respectively. 6.4 Mean growth inhibition (MGI) percentage of E.coli, H. pylori, S. aureus, against bifidocin B and yeast extract at 6.125, 12.5 and 25 mg. The MGI of E. coli was 14.45, 24.52, 48.36 of bifidocin B and 10.0, 19.20 and 24.45% of yeast extract respectively, H. pylori was 10.24, 26.27, 44.25 of bifidocin B and 7.25, 20.25 and 30.75% of yeast extract respectively, S. aureus was 9.35, 22.15, 42.25 of bifidocin B and 9.15, 27.75 and 36.25 % of yeast extract respectively, 6.5 Antibiofilm activity of bifidocin B and Yeast extract on Biofilm formation It was found that, H. pylori, S. aureus have the ability to produce biofilm with strong type, 1.6, 1.4 and and E. coli produce moderate type of biofilm, 0.94,O D at 570 nm, respectively. The effect of Bifidocin B and yeast extract on biofilm inhibition of H. pylori was evaluated at sub (MICs) concentrations 25, 12.5, 6.125 mg/ml. The anti-biofilm activity of Bifidocin B was stronger than yeast extract. The biofilm inhibition effect was 81.25, 48.125 and 21.875, % while, the anti-biofilm effect of yeast extract showed only 28.125, to 9.375 and 0.0 % respectively. Biofilm inhibition of S. aureus using Bifidocin B and yeast extract at (MICs) concentrations 6.25, 3.125, 1.562, 0.782 mg/ml were showed successfully reduction in biofilm formation. The optical densities of produced biofilms were 0.50, 0.8, 1.2 and 1.3 OD with percentage reduction 62.29, 42.86, 14.29 and 7.14 respectively. yeast extract was strong inhibition compared to Bifidocin B on S. aureus biofilm ,the biofilm formation under potent yeast extract was 0.30, 0.42, 0.60 and 0.70 OD with attenuation percentages were 78.57, 70.00, 57.14 and 50.00 respectively. Both Bifidocin B and yeast extract showed strong anti-biofilm inhibition effect against E. coli biofilm at sub (MICs) concentrations 12.5, 6.125,3.125 and 1.562 mg/ml. , the biofilm formation under potent Bifidocin B were 0.03, 0.32, 0.65 and 0.75 OD with percentages reduction were 96.81, 65.96, 30.85 and 20.21. As well as yeast extract was showed inhibition effect of Biofilm formation were 0.20, 0.38, 0.56 and 0.71 OD with percentage reduction were 78.72,59.57,40.43 and 24.48 respectively. 6.6 Antifugal activity of Bifidocin B and Yeast extract : Two prebiotics, bifidocin B and yeast extract a good alternative to the use of traditional antifugal treatment. Two prebiotics were assessed by inhibition zones diameter against Candida albicans and Aspergillus niger and showed the different susceptibilities towards bifidocin B and yeast extract at concentration 6.125,12.5 and 25 mg and standard error of clear zones of inhibition. Candida albicans was recorded 15.13, 19.35, 23.86 of bifidocin B and 16.21, 21.0 and 24.42 mm of yeast extract respectively. Aspergillus niger was recorded 12.15, 15.35, 18.52 mm of bifidocin B and 13.26, 15.25and 17.14 mm of yeast extract respectively.